← FDA DRUG APPROVALS

FDA NDA · NDA020759

TROVAN

Sponsor: PFIZER

APPLICATION
NDA020759
TYPE
NDA
ORIGINAL APPROVAL
1997-12-18
LATEST ACTION
2000-05-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

TROVANDiscontinued
TROVAFLOXACIN MESYLATE EQ 200MG BASE · TABLET · ORAL
TROVANDiscontinued
TROVAFLOXACIN MESYLATE EQ 100MG BASE · TABLET · ORAL

Approval history

2000-05-17Labeling · Supplement 8 · standardAP
2000-05-17Labeling · Supplement 6 · standardAP
2000-05-17Labeling · Supplement 4 · standardAP
2000-05-17Labeling · Supplement 7 · standardAP
1999-04-15Manufacturing (CMC) · Supplement 5 · standardAP
1999-03-19Manufacturing (CMC) · Supplement 3 · standardAP
1999-02-17Manufacturing (CMC) · Supplement 2 · standardAP
1998-09-23Labeling · Supplement 1 · standardAP
1997-12-18Type 1 - New Molecular Entity · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →